Experience of Long-Term (9 Years) Administration of Tocilizumab in Female Patient with Systemic Onset Juvenile Arthritis: Case Study

• Main Authors: Maria I. Kaleda (Author), Irina P. Nikishina (Author), Tamara N. Pachkoria (Author)
• Format: Book
• Published: "Paediatrician" Publishers LLC, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1682-5527; 1682-5535; 10.15690/vsp.v21i3.2429
• Keywords: tocilizumab; systemic onset juvenile arthritis; children; neutropenia; clinical case; Pediatrics; RJ1-570
• Source: Вопросы современной педиатрии, Vol 21, Iss 3, Pp 265-272 (2022)

Background. Systemic onset juvenile arthritis is a chronic disease of childhood. Its severity is determined by systemic manifestations, high risk of complications, such as macrophage activation syndrome, interstitial lung disease, and persistent polyarthritis with severe functional disorders. Genetically engineered biological drugs administration significantly improves the prognosis in these patients, thus, there are many questions about the possibilities of successful treatment correction in order to maintain long-term remission in real clinical practice.Clinical case description. The results of long-term (9 years) administration of tocilizumab in female patient with early onset of systemic onset juvenile arthritis are presented. It has been shown that control over disease activity can be achieved via adjusting the drug dosage and the intervals between infusions.Conclusion. Tocilizumab significantly improves prognosis of patients with systemic onset juvenile arthritis at good safety profile of this treatment.